KR20130081929A - Composition comprising dieckol compound for treating insulin resistance or hyperinsulinemia - Google Patents

Abstract

PURPOSE: A composition for prevention and treatment of insulin resistance or hyperinsulinemia is provided to have an effect to alleviate and treat the insulin resistance and hyperinsulinemia by containing dieckol compound as an active ingredient which accelerates glucose absorption into the muscular cell in an animal model in which the glucose absorption into the muscular cell is lowered due to the insulin resistance, and increasing activation of the GLUT-4 protein. CONSTITUTION: A composition for prevention or treatment of hyperinsulinemia contains dieckol compound represented by Chemical formula as an active ingredient. The dieckol compound increases the expression of Akt, AMPK and GLUT4 and accelerates the glucose absorption into the muscular cell. A composition for prevention or treatment the insulin resistance contains dieckol compound represented by Chemical formula as an active ingredient. Food for prevention or alleviation of hyperinsulinemia and insulin resistance contains dieckol compound represented by Chemical formula as an active ingredient. [Reference numerals] (AA) Content of insulin in the blood; (BB) Control group; (CC) Diethyl-injected group

Description

Composition comprising dieckol compound for treating insulin resistance or hyperinsulinemia}

The present invention relates to a novel use of diethol compounds for the treatment of insulin resistance and hyperinsulinemia and to increase glucose uptake in muscle cells.

Insulin is a type of hormone produced by β cells in the islet of Langelhans of the pancreas, and acts on lipid metabolism and protein metabolism as well as glucose metabolism through insulin receptors present in insulin target tissues such as skeletal muscle, liver and fat. It plays an important role in maintaining homeostasis. The action of insulin in each target tissue may include the promotion of glucose in the blood into muscle cells or adipocytes, the promotion of glycogen production in the liver and muscle tissues, the suppression of gluconeogenesis in the liver, and the fat cells. Glucose consumption, promotion of fatty acid synthesis, inhibition of lipid degradation, and the like.

Insulin resistance refers to a condition in which insulin or more is required to obtain various actions of insulin at the cellular, organ, and individual levels, that is, an insulin insufficiency state with reduced sensitivity to insulin. Hypertension, diabetes mellitus, hyperlipidemia (hypertriglycerideemia, hypo-HDL cholesterol), obesity, etc. are considered to be a condition based on insulin resistance from the results of conventional epidemiological examination. Insulin resistance results in a target hyperinsulinemia for blood sugar maintenance due to lack of insulin in glucose metabolism, causes hyperglycemia and impaired glucose tolerance, and progresses diabetes due to pancreatic β cell lung. In addition, hyperinsulinemia promotes sympathetic hyperactivity and the absorption of sodium in the kidneys to develop hypertension, and postprandial hyperlipidemia, hyperuricemia, and plasminogen activator inhibitor-1 (PAI-1). It also raises.

On the other hand, insulin resistance induces lipid metabolism abnormality due to lack of insulin, and free fatty acid (FFA) released from fat cells increases in the liver, which promotes triglyceride (TG) synthesis in the liver. And become TGemia. In addition, since lipoprotein lipase (LPL), which has high insulin sensitivity, is generally deactivated in an insulin resistant state, degradation of TG is reduced, and hypertension is exacerbated. In addition, as diabetes progresses, complications such as retinopathy, nephropathy, and necrosis due to vascular disorders coexist, and atherosclerosis and cerebral infarction, which are atherosclerosis diseases, progress, and hypertension promotes circulatory disease. As described above, insulin resistance is thought to be greatly involved in the exacerbation of complex conditions (insulin resistance and lifestyle diseases, Shimamoto Kazuaki editorial, diagnosis and therapist, 2003, pp. 1-5).

As a result, many drugs for improving insulin resistance have been developed. In particular, biguanides for inhibiting glycogenesis in the liver and thiazolidine derivatives for improving insulin sensitivity of muscle and adipose tissue have been developed. Thiazolidine derivatives, typified by troglitazone or pioglitazone, act as ligands of the peroxysome proliferator-activated receptor (PPAR), an intranuclear receptor-type transcription factor, promoting insulin differentiation by promoting the differentiation of fat cells. It is thought to improve resistance.

In addition, as related documents, adiponectin or an insulin resistance improving agent (International Patent Publication No. WO03 / 063894) having an active ingredient thereof, an ethyl acetate / butanol mixture extract or chloroform / methanol mixture extract, or a fraction thereof Insulin resistance improving agent (Korean Patent No. 0999317), containing a substance having affinity for bombesin receptor subtype 3 (BRS-3) as an active ingredient preventing and treating diseases caused by insulin resistance (Japanese Patent Publication No. 10-298100).

However, until now, there has been no use for improving insulin resistance based on the promotion of glucose uptake in muscle cells of dietol compounds.

Accordingly, the present inventors confirmed that the dietol compound has a function of promoting glucose absorption in excellent muscle cells, and can rapidly increase the metabolism of glucose already absorbed in the body, thereby improving or treating insulin resistance and hyperinsulinemia. This invention was completed.

Accordingly, an object of the present invention is to provide a composition for preventing or treating hyperinsulinemia and insulin resistance containing a diethol compound.

It is also an object of the present invention to provide a food for preventing or improving hyperinsulinemia and insulin resistance, which contains a dieteck compound as an active ingredient.

In order to achieve the above object, the present invention provides a composition for preventing or treating hyperinsulinemia containing a dieteckol compound as an active ingredient.

In one embodiment of the present invention, the diecol compound increases the expression of Akt, AMPK and GLUT4 to promote glucose uptake into muscle cells.

In order to achieve the above object, the present invention provides a composition for the prevention or treatment of insulin resistance containing a dieckol compound as an active ingredient.

In one embodiment of the present invention, the diecol compound increases the expression of Akt, AMPK and GLUT4 to promote glucose uptake into muscle cells.

In addition, the present invention provides a composition for promoting glucose uptake in muscle cells containing a diethol compound as an active ingredient.

In addition, the present invention provides a food for preventing or improving hyperinsulinemia and insulin resistance, which contains a dieckol compound as an active ingredient.

The present invention relates to a composition for treating insulin resistance and hyperinsulinemia containing a diethol compound as an active ingredient, wherein the diethol compound is reduced to muscle cells in an animal model in which glucose uptake into muscle cells is reduced due to insulin resistance. It has the effect of promoting glucose uptake and increasing the activity of GLUT-4 protein to improve and treat insulin resistance and hyperinsulinemia.

1 is a graph measuring the degree of glucose uptake into dietary cells of muscle.
2 is a result of Western blot analysis for the investigation of glucose absorption mechanism mechanism of dietol into muscle cells.
Figure 3 is a graph measuring the effect of inhibiting the blood insulin content of dietol type 2 diabetic rats.
Figure 4 is a graph measuring the change in blood glucose concentration of dietol type 2 diabetic rats.

The present invention relates to a composition for the prevention and treatment of hyperinsulinemia and insulin resistance comprising a dieteckol compound, and more particularly, to a signaling system for promoting the absorption of glucose into cells in the diethol compound. Insulin resistance and hyperinsulinemia can be resolved by promoting expression of Akt (insulin-dependent) and AMPK (insulin-independent) proteins, and inducing GLUT4 expression to increase glucose uptake into muscle cells.

Insulin plays a role in promoting the introduction of glucose into the blood into muscle cells and adipocytes. Patients with insulin resistance are not absorbed into the muscle cells, etc., even though insulin is secreted into the body. As a result, blood insulin is maintained.

Accordingly, the present inventors have confirmed that the dietol compound known in the art to facilitate the absorption of glucose into the muscle cells in the blood, the dietol compound can solve hyperinsulinemia and resolve insulin resistance in real animal models Based on the present invention was completed.

Therefore, the present invention is characterized by providing a composition for the prevention or treatment of hyperinsulinemia or insulin resistance, which contains a dieteck compound as an active ingredient.

The dieckol compound has a molecular formula of C ₃₆ H ₂₂ O ₁₈ and is a phloroglucinol and tannin-based compound and is an algae of Ecklonia species such as Ecklonia cava. It is known to contain a lot of structural formula, Dibenzo [b, e] [1,4] dioxin-1,3,6,8-tetrol, 4- [4- [6- (3,5-dihydroxyphenoxy) -4 , 7,9-trihydroxydibenzo [b, e] [1,4] dioxin-2-yl] oxy] -3,5-dihydroxyphenoxy]-and the chemical formula is as follows.

≪

The diecol compound according to the invention may be used in the form of a salt, preferably a pharmaceutically acceptable salt. The salt is preferably an acid addition salt formed by a pharmaceutically acceptable free acid, and the free acid may be an organic acid or an inorganic acid. The organic acids include, but are not limited to, citric, acetic, lactic, tartaric, maleic, fumaric, formic, propionic, oxalic, trifluroacetic, benzoic, gluconic, methosulfonic, glycolic, succinic, Glutamic acid and aspartic acid. The inorganic acid includes, but is not limited to, hydrochloric acid, bromic acid, sulfuric acid, and phosphoric acid.

Dieeckol according to the present invention can be isolated from nature or prepared by chemical synthesis known in the art, and preferably can be isolated and purified from natural plants. That is, it can be obtained from a plant or part of a plant using a method of extracting and separating conventional materials. The stems, roots or leaves of natural plants are appropriately dried and macerated or only dried to obtain the desired extracts and extracted with a suitable organic solvent, and the desired extracts are known to those skilled in the art. It can be purified using. Most preferably the dieckol compounds of the present invention can be isolated and purified from ecstasy.

As diabetes increases rapidly today, specific therapeutic agents are being developed to solve specific diseases and root causes. Individual studies are being conducted on pre-conditions that can lead to diabetes, such as hyperinsulinemia or insulin resistance, rather than just drugs that reduce blood sugar.

 Insulin resistance indicates a weak state of glucose absorption promoting action, which is the main action of insulin in skeletal muscle, fat cells and liver. Insulin resistance refers to a condition in which systemic tissues, such as muscle, liver, and fat, are insensitive to insulin. In the state where insulin resistance develops, the insulin sensitivity of a tissue falls and insulin-dependent sugar uptake ability falls. As a result, the effect of lowering blood sugar by insulin is reduced.

This leads to the development of compensatory hyperinsulinemia and is understood to be the essence of the condition of the disease, especially in type 2 diabetic patients. Therefore, it is considered useful to increase the insulin-dependent glucose absorption of tissues by using insulin resistance improving agents as well as diabetic drugs such as hypoglycemic agents in the treatment of type 2 diabetes, and many drugs have been developed and used in clinical practice. have.

On the other hand, hyperinsulinemia refers to a high state of insulin levels in blood and is divided into organic and functional. The former is caused by proliferation (adenoma, hypertrophy) of the island of Langerhans, resulting in excessive secretion of insulin from the pancreas and spontaneous hypoglycemia. Hypoglycemic symptoms (vibration, cold sweats, exhaustion, loss of consciousness) occur at an early fasting time, and the blood sugar level is lower than 50 mg / ㎗ and the sugars are recovered immediately (when whipping).

Functional hyperinsulinemia is caused by autonomic nerves and dysfunction of the digestive system, mainly due to autonomic nerves and dysfunction of the digestive system, causing hypoglycemia 2-4 hours after eating (when gastrointestinal stroke, hepatitis, etc.). High blood insulin levels due to the rare presence of insulin autoantibodies (insulin autoimmune syndrome), high blood insulin levels due to the presence of abnormal insulin in mild diabetes. Hyperinsulinemia due to abnormalities in insulin receptors. An example of seeing hypoglycemia is reported.

As such, hyperinsulinemia is not limited to diabetes but is caused by various causes, and is known as an important cause of lipid metabolism disorder, hypertension and coronary atherosclerosis.

Therefore, hyperinsulinemia and insulin resistance are one of the metabolic diseases that threaten the health of modern people, and their prevention and treatment are very important.

However, not all of the currently used hyperinsulinemia and insulin resistance improving agents have the potential to cause serious side effects that make continuous treatment difficult. In fact, many cases of side effects such as liver dysfunction, edema, weight gain, and fat tissue weight increase have been reported, and discontinuation or discontinuation of treatment has been reported. It is a factor.

Researchers are beginning to pay attention to the muscles that make up 45% of our body for the treatment of insulin resistance and hyperinsulinemia, which can keep patients healthy without any side effects. Existing insulin resistance modifiers are intended to induce functional recovery of insulin mediated only by insulin-dependent responses, such as increased glucose uptake into fat cells and promoting glycogen synthesis in liver tissues to lower insulin blood levels and improve tissue resistance. I tried. However, unlike fat or hepatocytes, where glucose is increased only by the response of insulin, muscle cells can enter glucose through insulin-dependent and insulin-independent pathways.

In the insulin-dependent Akt pathway, when insulin secreted for glycemic control is combined with the insulin recepter (IR) on the cell membrane, it is a series of insulin signaling systems, insulin receptor substrate-1 (IRS-1)-phosphatidylinositol-3-kinase ( PI3-Kinase) finally activates the process of Akt and increases glucose uptake by increasing the transport of glucose transporter GLUT4 into the cell membrane in the cytoplasm.

On the other hand, AMPK (AMP-activated protein kinase), an insulin-independent pathway, is an energy-sensing enyme and acts as an important factor for intracellular glucose metabolism. Recently, exercise, known as a typical stimulus to increase glucose influx in muscle cells along with insulin, increases the transport of glucose transporter GLUT4 to the cell membrane through a path independent of the existing insulin signaling system through AMPK activation. It is known to increase glucose uptake in cells. Indeed, there are reports that representative treatments of type 2 diabetes such as metformin or rosiglitazone induce insulin resistance improvement through the activation of intramuscular AMPK, and there is increasing interest in the action of this enzyme in the field of diabetes.

In this regard, the diecol compound according to the present invention has an excellent effect of activating both the insulin-dependent Akt pathway as well as the insulin-independent AMPK pathway, thereby excellently increasing the cell membrane migration of the glucose transporter GLUT4 into muscle cells. By smoothing the transport of glucose, there is an effect that can be excellently treated for hyperinsulinemia due to insulin resistance.

That is, according to one embodiment of the present invention, it was confirmed that the dietol compound increases the glucose uptake into concentration-dependently into differentiated muscle cells (see FIG. 1), and as a result of elucidating the specific mechanism of promoting glucose uptake, muscle Activated both Akt (insulin-dependent) and AMPK (insulin-independent), which are essential for glucose uptake into the cell, and also increased expression of GLUT4, a glucose transporter, allowing GLUT4 to move to the cell membrane and facilitate glucose uptake into cells. Was confirmed (see FIG. 2).

In addition, according to an embodiment of the present invention, as a result of ingesting the diecol compound according to the present invention in an animal model showing hyperinsulinemia, it was confirmed that the blood concentration of insulin was excellently lowered (see FIG. 3). As a result, the concentration of glucose in the blood was also lowered (see FIG. 4). As a result, it was confirmed that the hyperinsulinemia was improved through the diecol compound. In addition, it was confirmed that the insulin resistance can be improved by solving the glucose absorption action into muscle cells that occur off insulin sensitivity.

Therefore, the present invention can be used as a composition for preventing or treating hyperinsulinemia or insulin resistance, which contains a diethol compound as an active ingredient, wherein the diethol compound increases the expression of Akt, AMPK and GLUT4 to glucose into muscle cells. It is characterized by promoting absorption.

Thus, the present invention provides a composition for promoting glucose uptake in muscle cells containing a diecol compound as an active ingredient.

The composition of the present invention can be used as a pharmaceutical composition for the prevention or treatment of hyperinsulinemia or insulin resistance. The composition may comprise 0.1 to 50% by weight of the dietol compound relative to the total weight of the composition.

In addition, the composition according to the present invention may include a pharmaceutically effective amount of a diecol compound alone or may include one or more pharmaceutically acceptable carriers, excipients or diluents. The pharmaceutically effective amount herein refers to an amount sufficient to prevent, ameliorate and treat insulin resistance or hyperinsulinemia. The pharmaceutically effective amount of the diethol compound according to the present invention is 0.5-100 mg / day / kg body weight, preferably 0.5-5 mg / day / kg body weight. However, the pharmaceutically effective amount may be appropriately changed depending on the symptom of the disease, the age, body weight, health condition, sex, administration route and treatment period of the patient.

In addition, "pharmaceutically acceptable" as used herein refers to a composition which is physiologically acceptable and does not normally cause an allergic reaction such as gastrointestinal disorders, dizziness or the like when administered to a human. Examples of such carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil. Further, it may further include a filler, an anticoagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and an antiseptic agent.

In addition, the compositions of the present invention may be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. The formulations may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders.

The composition according to the present invention may be administered through various routes including oral, transdermal, subcutaneous, intravenous or muscular, and the dose of the active ingredient may be varied depending on various factors such as route of administration, age, sex, And the like.

In addition, the composition of the present invention can be administered in parallel with known compounds having the effect of preventing, improving or treating insulin resistance or hyperinsulinemia.

Furthermore, the composition according to the present invention not only provides the effect of relieving insulin resistance or hyperinsulinemia through the effect of promoting glucose uptake into the excellent muscle cells, but also has no other toxicity and side effects in the human body, so it can be used safely in long-term use. Can be.

Therefore, the composition of the present invention can be added to a food for the purpose of preventing or treating hyperinsulinemia and insulin resistance, and thus can be used as a food composition for the prevention and improvement of hyperinsulinemia or insulin resistance symptoms.

That is, the present invention provides a food for preventing or improving hyperinsulinemia and insulin resistance containing a dieteckol compound represented by the following formula as an active ingredient.

≪

The diecol compound may be easily used as a food, such as a main ingredient, an auxiliary ingredient, a food additive, a functional food or a beverage, which is effective in preventing and improving the hyperinsulinemia or insulin resistance symptoms.

In the present invention, the "food" means a natural product or processed product containing one or more nutrients, and preferably means a state in which it can be directly eaten through a certain processing step, and a general meaning As used herein, it refers to food, food additives, functional foods and beverages.

Foods to which the composition according to the present invention can be added include, for example, various foods, beverages, gums, tea, vitamin complexes, and functional foods. In addition, in the present invention, the food may include special nutritive foods (e.g., crude oil, spirits, baby food, etc.), meat products, fish meat products, tofu, mackerel, noodles (Such as soy sauce, soybean paste, kochujang, mixed potatoes), sauces, confectionery (eg, snacks), candies, chocolate, gums, ice cream, milk products (eg, fermented milk, cheese, But are not limited to, pickled foods (various kinds of kimchi, pickles, etc.), beverages (e.g., fruit drinks, vegetable beverages, beverages, fermented beverages and the like) and natural seasonings (e.g. The food, beverage or food additive may be prepared by a conventional production method.

In addition, the term "functional food" refers to the control of biological defense rhythms and disease prevention of food groups or food compositions that have added value to the food by using physical, biochemical, or biotechnological techniques to act and express the function of the food for a specific purpose. It means a food that is designed and processed to fully express the body's regulatory function regarding recovery and the like, and specifically, it may be a health functional food. The functional food may include a food-acceptable food-aid additive, and may further comprise suitable carriers, excipients and diluents conventionally used in the production of functional foods.

In addition, in the present invention, the term "beverage" refers to a generic term for drinking to quench thirst or to enjoy a taste and includes a functional drink. The beverage is not particularly limited in addition to including the composition according to the present invention as an essential ingredient in the ratio indicated, and may contain various flavors or natural carbohydrates and the like as additional ingredients, as in the usual beverage.

Furthermore, the food containing the composition of the present invention in addition to the above-mentioned composition can be used as a food such as various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers (cheese, And carbonates used in alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonated drinks, etc., and these components may be used independently or in combination Can be used.

In the food containing the composition of the present invention, the amount of the composition according to the present invention may be 0.001% by weight to 90% by weight, preferably 0.1% by weight to 40% by weight, And in the case of beverages, it may be contained in a proportion of 0.001 g to 2 g, preferably 0.01 g to 0.1 g based on 100 ml. However, in the case of long-term intake for health and hygiene purposes or for health control purposes, And since the active ingredient has no problem in terms of safety, it can be used in an amount of more than the above range, so it is not limited to the above range.

Therefore, the present invention can provide a dietary supplement for preventing or improving insulin resistance or hyperinsulinemia containing a dietary alcohol compound according to the present invention, but the form of the food is not limited thereto. , Tablet, capsule or beverage form.

Hereinafter, the present invention will be described in detail with reference to the following examples and experimental examples. However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the contents of the present invention are not limited by the following Experimental Examples.

< Example  1>

The Diecole Into muscle cells  Determination of the effect on glucose absorption

In order to determine the effect of the dietary alcohol of the present invention on glucose uptake into muscle cells, the following experiment was performed.

<1-1> Cell Culture and Differentiation

The muscle cells (L6) used in the experiment were purchased from Korean Cell Line Bank and cultured in DMEM medium supplemented with 10% FBS and 1% antibiotics at 37 ° C in a 5% CO ₂ incubator. If the undifferentiated muscle cells (L6) were 70 to 80%, DMEM medium supplemented with 2% horse serum was added and the differentiation was induced for 7 days and the medium was changed every 2 days.

<1-2> Into muscle cells  Glucose absorption measurement

Differentiated muscle cells were starvated in serum-free DMEM medium for 4 hours and washed with PBS. Subsequently, it was replaced with fresh serum-free DMEM, treated with a diecol compound, incubated for 30 minutes, and insulin treated as a control was reacted for 10 minutes. Glucose uptake was measured by measuring the amount of glucose contained in the medium to calculate the amount of glucose transferred into the cells. The calculated degree of glucose uptake into the muscle cells of dietol is shown in FIG.

As a result, it was confirmed that dietol increased glucose uptake into muscle cells in a concentration-dependent manner, and showed a glucose-like glucose uptake effect at dietol 50 uM concentration. From this result, it was confirmed that dietol has the effect of promoting glucose uptake into muscle cells.

<1-3> Into muscle cells  For following glucose absorption mechanism Western Blat  analysis

Differentiated muscle cells were starvated in serum-free DMEM medium for 4 hours and washed with PBS. Subsequently, it was replaced with fresh serum-free DMEM, treated with diecol (50 uM), incubated for 30 minutes, and the insulin used as a control was reacted for 10 minutes after treatment. After the completion of the reaction, the cells were collected and the cells were eluted with lysis buffer. The cell eluate was separated into cell membrane and cytoplasm again, and the protein content was measured, respectively. The expression of GLUT4 contained in the same amount of membrane protein was determined using anti-GLUT4 antibody, and the phospho-Akt and phospho-AMPK contained in the same amount of cytoplasmic protein The expression patterns of were measured by immunoblotting using anti-phospho-Akt (Ser 473) and anti-phospho-AMPK (Thr 172), respectively. Each protein expression pattern measured is shown in FIG. 2.

As a result, it was confirmed from Figure 2 that dietol increases the amount of protein expression of Akt (insulin-dependent) and AMPK (insulin-independent) and GLUT4, which are essential for glucose uptake into muscle. Glucose uptake into muscle cells is known that GLUT4, a glucose transporter, moves to the cell membrane by the activation of Akt and AMPK, and glucose is absorbed into cells. In this example, it was found that dietol activated both Akt and AMPK, and GLUT4 expression was also increased, and GLUT4 moved to the cell membrane to facilitate glucose uptake into cells.

< Example  2>

According to the invention Diecol  In animal models of compounds Hyperinsulinemia  Improvement effect

Five-week-old male ICRC57BL / 6 db / db mice were purchased from a central laboratory animal and used for experiments after adapting to a general diet for 4 weeks. The experimental group was randomly assigned to the control group, dietol 10 mg / kg B.W administration group, dietol 20 mg / kg B.W administration group. The experiment was conducted for a total of two weeks, and the diecol-administered group was administered intraperitoneally once a day at the above doses. The temperature and humidity of the breeding room were maintained at 20 ± 2 ° C and 50 ± 10%, and the darkness and the humidity were adjusted at intervals of 12 hours.

Body weight and fasting blood glucose were measured at a constant time during the experiment. Fasting blood glucose was measured by fasting the db / db mice for 12 hours every night and then collecting blood from the tail vein. After two weeks of experiments, blood was collected from db / db mice and centrifuged to separate plasma. Insulin concentrations were measured using the separated plasma using a Rat / Mouse Insulin ELISA kit following the ELISA method.

First, suffer from insulin resistance ingesting the dietol compound of the present invention As a result of examining the change of blood insulin concentration in the insulin-independent type 2 diabetic model mice, the blood insulin content in the type 2 diabetic model rats ingested nothing as a control group was 9.8 ng / ml as shown in FIG. 3. Compared to 2 ~ 3 ng / ml, the blood insulin content of rats is very high.

However, it can be seen that the concentration of insulin in the blood of the model rats administered with the dietol compound for two weeks from the start of the experiment was significantly reduced. Especially In the case of dietol 20 mg / kg administration group, the blood insulin content was 5.2 ng / ml, compared to the control group was confirmed that the blood insulin content is about 2 times lower. From the above results, the inventors have found that the dietol compound has an effect of improving and treating hyperinsulinemia and accompanying insulin resistant diseases.

In addition, as a result of confirming the change in blood glucose of the model rats, as shown in Figure 4, the administration group of dietol according to the present invention was found to exhibit a continuous decrease in blood glucose compared to the control group.

Therefore, the inventors of the present invention, the dietary compound according to the present invention promotes the expression of Akt (insulin-dependent) and AMPK (insulin-independent) and GLUT4 to promote glucose uptake into cells, thereby triggering the consumption of glucose already absorbed into the body. In addition, the insulin content in the blood was lowered and the insulin resistance was resolved. The blood glucose level was also lowered.

In this example, all experimental results were expressed as mean ± standard deviation using SAS program, and significance was pretested by one-way ANOVA and post-tested by Duncan's multiple range test. The statistical significance level was obtained when the P value was less than 0.05.

So far I looked at the center of the preferred embodiment for the present invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.

Claims (5)

A composition for preventing or treating hyperinsulinemia, containing a dieteckol compound represented by the following formula as an active ingredient:
&Lt;

. The method of claim 1,
The dietic compound is a composition for preventing or treating hyperinsulinemia, characterized in that to promote the absorption of glucose into muscle cells by increasing the expression of Akt, AMPK and GLUT4. A composition for preventing or treating insulin resistance, containing a dieckol compound represented by the following formula as an active ingredient:
&Lt;

. The method of claim 3,
The dietary compound is a composition for preventing or treating insulin resistance, characterized in that to promote the absorption of glucose into muscle cells by increasing the expression of Akt, AMPK and GLUT4. A food for preventing or improving hyperinsulinemia and insulin resistance containing a dieteck compound represented by the following formula as an active ingredient:
&Lt;

.

Images